These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 18380795)
1. Downregulation of Tie2 gene by a novel antitumor sulfolipid, 3'-sulfoquinovosyl-1'-monoacylglycerol, targeting angiogenesis. Mori Y; Sahara H; Matsumoto K; Takahashi N; Yamazaki T; Ohta K; Aoki S; Miura M; Sugawara F; Sakaguchi K; Sato N Cancer Sci; 2008 May; 99(5):1063-70. PubMed ID: 18380795 [TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenesis effect of 3'-sulfoquinovosyl-1'-monoacylglycerol via upregulation of thrombospondin 1. Matsuki K; Tanabe A; Hongo A; Sugawara F; Sakaguchi K; Takahashi N; Sato N; Sahara H Cancer Sci; 2012 Aug; 103(8):1546-52. PubMed ID: 22587436 [TBL] [Abstract][Full Text] [Related]
3. Alpha-sulfoquinovosylmonoacylglycerol is a novel potent radiosensitizer targeting tumor angiogenesis. Sakimoto I; Ohta K; Yamazaki T; Ohtani S; Sahara H; Sugawara F; Sakaguchi K; Miura M Cancer Res; 2006 Feb; 66(4):2287-95. PubMed ID: 16489033 [TBL] [Abstract][Full Text] [Related]
4. Inhibitory action of emulsified sulfoquinovosyl acylglycerol on mammalian DNA polymerases. Mizushina Y; Maeda N; Kawasaki M; Ichikawa H; Murakami C; Takemura M; Xu X; Sugawara F; Fukumori Y; Yoshida H; Sakaguchi K Lipids; 2003 Oct; 38(10):1065-74. PubMed ID: 14669972 [TBL] [Abstract][Full Text] [Related]
5. Analysis of cell cycle regulation by 1-mono-O-acyl-3-O-(alpha-D-sulfoquinovosyl)-glyceride (SQMG), an inhibitor of eukaryotic DNA polymerases. Murakami C; Takemura M; Yoshida H; Sugawara F; Sakaguchi K; Mizushina Y Biochem Pharmacol; 2003 Aug; 66(4):541-50. PubMed ID: 12906919 [TBL] [Abstract][Full Text] [Related]
7. Structure-function relationship of synthetic sulfoquinovosyl-acylglycerols as mammalian DNA polymerase inhibitors. Murakami C; Yamazaki T; Hanashima S; Takahashi S; Ohta K; Yoshida H; Sugawara F; Sakaguchi K; Mizushina Y Arch Biochem Biophys; 2002 Jul; 403(2):229-36. PubMed ID: 12139972 [TBL] [Abstract][Full Text] [Related]
8. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175 [TBL] [Abstract][Full Text] [Related]
9. Studies on a novel DNA polymerase inhibitor group, synthetic sulfoquinovosylacylglycerols: inhibitory action on cell proliferation. Ohta K; Hanashima S; Mizushina Y; Yamazaki T; Saneyoshi M; Sugawara F; Sakaguchi K Mutat Res; 2000 May; 467(2):139-52. PubMed ID: 10838201 [TBL] [Abstract][Full Text] [Related]
10. Mechanism of cell cycle arrest by sulfoquinovosyl monoacylglycerol with a C18-saturated fatty acid (C18-SQMG). Murakami C; Miuzno T; Hanaoka F; Yoshida H; Sakaguchi K; Mizushina Y Biochem Pharmacol; 2004 Apr; 67(7):1373-80. PubMed ID: 15013853 [TBL] [Abstract][Full Text] [Related]
11. Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoetin-2 ligands as candidates for anti-angiogenesis therapy. Shlamkovich T; Aharon L; Barton WA; Papo N Oncotarget; 2017 May; 8(20):33571-33585. PubMed ID: 28422724 [TBL] [Abstract][Full Text] [Related]
12. Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Lewis CE; De Palma M; Naldini L Cancer Res; 2007 Sep; 67(18):8429-32. PubMed ID: 17875679 [TBL] [Abstract][Full Text] [Related]
13. Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model. Raikwar SP; Temm CJ; Raikwar NS; Kao C; Molitoris BA; Gardner TA Mol Ther; 2005 Dec; 12(6):1091-100. PubMed ID: 16169279 [TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship of a novel group of mammalian DNA polymerase inhibitors, synthetic sulfoquinovosylacylglycerols. Hanashima S; Mizushina Y; Ohta K; Yamazaki T; Sugawara F; Sakaguchi K Jpn J Cancer Res; 2000 Oct; 91(10):1073-83. PubMed ID: 11050480 [TBL] [Abstract][Full Text] [Related]
15. Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. Zhang ZL; Liu ZS; Sun Q World J Gastroenterol; 2006 Jul; 12(26):4241-5. PubMed ID: 16830384 [TBL] [Abstract][Full Text] [Related]
16. An emulsion of sulfoquinovosylacylglycerol with long-chain alkanes increases its permeability to tumor cells. Aoki S; Ohta K; Matsumoto K; Sakai H; Abe M; Miura M; Sugawara F; Sakaguchi K J Membr Biol; 2006; 213(1):11-8. PubMed ID: 17347779 [TBL] [Abstract][Full Text] [Related]
17. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496 [TBL] [Abstract][Full Text] [Related]
18. Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model. Nakazawa Y; Kawano S; Matsui J; Funahashi Y; Tohyama O; Muto H; Nakagawa T; Matsushima T Cancer Sci; 2015 Feb; 106(2):201-7. PubMed ID: 25458359 [TBL] [Abstract][Full Text] [Related]
19. Specific interaction between an oligosaccharide on the tumor cell surface and the novel antitumor agents, sulfoquinovosylacylglycerols. Ohta K; Mizushina Y; Yamazaki T; Hanashima S; Sugawara F; Sakaguchi K Biochem Biophys Res Commun; 2001 Nov; 288(4):893-900. PubMed ID: 11688993 [TBL] [Abstract][Full Text] [Related]